key: cord-0967376-31t2ctmo authors: Schaller, Matthew A.; Sharma, Yamini; Dupee, Zadia; Nguyen, Duy; Uruena, Juan; Smolchek, Ryan; Loeb, Julia C.; Machuca, Tiago N.; Lednicky, John A.; Odde, David J.; Campbell, Robert F.; Sawyer, W. Gregory; Mehrad, Borna title: In vitro infection of human lung tissue with SARS-CoV-2: Heterogeneity in host defense and therapeutic response date: 2021-01-21 journal: bioRxiv DOI: 10.1101/2021.01.20.427541 sha: e444e5025cf183019aebd75339282da78e0c3637 doc_id: 967376 cord_uid: 31t2ctmo Cell lines are the mainstay in understanding the biology of COVID-19 infection, but do not recapitulate many of the complexities of human infection. The use of human lung tissue is one solution for the study of such novel respiratory pathogens. We hypothesized that a cryopreserved bank of human lung tissue allows for the in vitro study of the inter-individual heterogeneity of host response to SARS-CoV-2 infection, thus providing a bridge between studies with cell lines and studies in animal models. We generated a cryobank of tissues from 16 donors, most of whom had risk factors for severe illness from COVID-19. Cryopreserved tissues preserved 90% of cell viability and contained heterogeneous populations of metabolically active epithelial, endothelial, and immune cell subsets of the human lung. Samples were readily infectible with HCoV-OC43 and SARS-CoV-2 coronavirus strains, and demonstrated comparable susceptibility to infection. In contrast, we observed a marked donor-dependent heterogeneity in the expression of IL-6, CXCL8 and IFNβ in response to SARS-CoV-2 infection. Treatment of tissues with dexamethasone and the experimental drug, N-hydroxycytidine, suppressed viral growth in all samples, whereas chloroquine and remdesivir had no detectable effect. Metformin and sirolimus, molecules with predicted antiviral activity, suppressed viral replication in tissues from a subset of donors. In summary, we developed a novel system for the in vitro study of human SARS-CoV-2 infection using primary human lung tissue from a library of donor tissues. This model may be useful for drug screening and for understanding basic mechanisms of COVID-19 pathogenesis. Importance The current biological systems for the study of COVID-19 are in vitro systems that differ from the human lung in many respects, and animal hosts to which the virus is not adapted. We developed another alternative for studying pathogenesis and drug susceptibility of SARS-CoV-2 in a cryopreserved bank of human lung tissues. We consider the importance of this work to relate to the practical use of this culture system as a repeatable and scalable approach that allows for the study of an important infection in relevant tissues. The tissue bank highlights the heterogeneous response to SARS-CoV-2 infection and treatment, which allows researchers to investigate why treatments work in some donors but not others. The COVID-19 pandemic has highlighted the need for improved models of infection to study host-pathogen interactions, rapidly screen potential therapeutic interventions, and study fundamental pathogenic mechanisms. Cell lines have served as the mainstay in understanding the biology of the infection, but do not capture the cellular heterogeneity, cell-cell and cell-matrix interactions, or between-host variability encountered in human infection. The use of human lung tissue is one solution for the study of biology of novel respiratory pathogens. Lung tissue explants capture the cellular heterogeneity within the human lung and the use of tissues from multiple donors can allow the study of the genetic diversity found within the human population. To this end, human lung organoids (1, 2) and lung-on-a-chip organs (3) are readily infected with SARS-CoV-2. The use of these models is limited by two considerations: first, there are practical difficulties of repeating experiments with the same donor or performing experiments on multiple donors in parallel. Second, these are simplified systems that do not recapitulate the intrinsic complexities of lung tissue. The optimal solution to these problems is a repeatable and scalable in vitro system that captures the intricacies of the human lung while allowing high-throughput parallel drug screens from multiple donors and sequential experiments using tissue from the same donor. Polyampholytes are polymeric hydrogels composed of poly-L lysine or other amphiphilic chemicals that can serve as a less toxic alternative to dimethylsulfoxide for the cryopreservation of cells. Similar to antifreeze proteins first discovered in arctic fish (4) , these amphiphilic proteins interact with both the hydrophobic cell membrane and hydrophilic ice crystals, mitigating damage associated with the formation of crystals during freezing (5) (6) (7) . Polyampholyte medias have been used to cryopreserve many cell lines and primary cells with high viability (8) . Recent work has demonstrated that they can also be used to cryopreserve 3D cell structures (9) . We therefore tested the hypothesis that a cryopreserved bank of human lung tissue allows for the in vitro study of the inter-individual heterogeneity of host response to SARS-CoV-2 infection, thus providing a bridge between studies with cell lines and studies in animal models. The study was performed in accordance with the Declaration of Helsinki, under a protocol approved by the University of Florida Institutional Review Board (IRB202000920) after written informed consent from participants. Lung tissues were obtained from participants undergoing lung resection surgery or from allografts that underwent volume reduction before transplantation. In cases of lung resection for nodules, samples far from the site of pathology were utilized. Pleural tissue and staple lines were dissected away, and the lung tissue was then sectioned into approximately 0.5g pieces. were water soluble and were compared to the infected but untreated control. Vero-E6 cells used to test inhibition of viral growth were cultured to an estimated 90% confluence in 96 well plates prior to testing and then infected with 10 4 PFU (approximating an MOI of 1) in viral growth media containing the specified drugs as described above. Probability value of <0.05 was considered statistically significant. We recruited 16 subjects, most of whom had at least one risk factor for severe COVID-19 infection, including old age and comorbidities ( Table 2) . We began by assessing the viability and integrity of cryopreserved lung tissue after 48 hours of culture. We found a comparable viability to fresh tissue when cultured for 48 h as measured by flow cytometry (Fig 1A-B) . All major subsets of cells were present in cryopreserved tissue, including epithelial cells, endothelial cells and leukocytes ( Figure 1C -D). T cells, defined by CD3+ staining, comprised 6.3% of the total cell population, whereas alveolar macrophages composed 1.8% and other monocytic phagocytes made up approximately 0.3%. Each leukocyte population is consistent with previous results in which a collagenase-based method is used to digest lung tissue (10), but flow cytometric analysis showed type 1 epithelial cells to constitute an estimated 4% of total viable cells within the samples, lower than approximately 8% of lung tissue reported in literature (11, 12) . We attribute this to the loss of fragile cells during processing for flow cytometry (13) . To obtain a more accurate measurement of epithelial cell viability, we imaged the samples using confocal microscopy after staining with Calcein AM, a cell-permeable viability dye that only fluoresces in metabolically active cells, and found an abundant population of viable cells with type I epithelial morphology within the samples ( Figure 1E ). We confirmed this finding by staining the cryopreserved samples with zona occludens-1 (ZO-1), which identifies intact tight junctions between lung epithelial cells (14) , and the epithelial cell marker E-cadherin ( Figure 1F-G) . We began by infecting lung samples from two donors with each of two human coronaviruses: HCoV-OC43, an endemic cause of the common cold (15, 16) that infects cells via cell membrane sialyl acid groups (17, 18) , and SARS-CoV-2. Both HCoV-OC43 and SARS-CoV-2 could infect cryopreserved tissues in a dose-dependent manner (Figure 2A -B) and both viruses were detectable within the tissues by immunofluorescence microscopy ( Figure 2C ). Interestingly, SARS-CoV-2 protein was also detectable outside the tissue, consistent with viral shedding. Surprisingly, we found a marked disparity in the IL6 transcriptional response to both coronaviruses between the two donors, with a 100 fold increase in one and no change in the other ( Figure 2D ). We next sought to better assess this variance in the host response to SARS-CoV-2 infection within our tissue bank. As expected, we found an inoculum-dependent increase in viral protein transcription ( Figure 3A-B) . We selected expression of IFNB1, IL6, and CXCL8 as markers of host response, representative of overlapping transcriptional responses to viral infection. We found highly heterogeneous responses among donors in response to the same viral inoculum, with a range of 0 to 34-fold induction in CXCL8, 0 to 85-fold induction in IL6, and 0 to 214-fold induction in IFNB1 ( Figure 3C -E). We found no correlation between the host response and age, sex, blood type, or presence of comorbidities in this cohort (data not shown). Comparison of cytokine induction within each donor showed that most donors displayed greater induction of cytokine transcription with higher viral inocula ( Figure 3F ). Within each donor, there was a strong correlation between the induction of IL6 and CXCL8 in response to both low and high viral inocula (r 2 >0.92), albeit with marked inter-individual variability, but no correlation between the expression of IFNB1 with either IL6 or CXCL8 (r 2 <0.1; Figure 3F and supplemental figure). We reasoned that drug testing for COVID-19 relies on in vitro infection of cell lines, which may not accurately represent the response of human tissue to infection. To assess this, we next tested the effect of six drugs on SARS-CoV-2 viral titer in lung tissue from five different donors and VeroE6 cells. We found that dexamethasone, a drug found to improve outcomes in COVID-19 infection (19), reduced viral titers in all donor tissues, but not in VeroE6 cells ( Figure 4A ). In contrast, chloroquine reduced viral titer in VeroE6 cells but not in the lung tissue donors ( Figure 4B ), consistent with prior research demonstrating that chloroquine does not inhibit viral titer in lung epithelial cells (20, 21) . Remdesivir, which has been variably effective in COVID-19 in clinical trials (22) (23) (24) , did not significantly affect viral titer in any of the in vitro infections ( Figure 4C ). Finally, we tested three investigational therapies previously predicted as potentially effective in SARS-CoV-2 infection, including sirolimus (25, 26) , metformin (27) (28) (29) , and Nhydroxycytidine (30) . We found that sirolimus was highly effective in reducing viral titer in tissues from three donors, but did not significantly affect titer in two donors or Vero cells ( Figure 4D ). A similar heterogeneity was observed with metformin ( Figure 4E ). N-hydroxycytidine, an experimental drug that inhibits viral transcription (30) , resulted in a significant reduction in viral titer in all tested samples ( Figure 4F ). These results highlight the considerable heterogeneity of antiviral host response and medication effectiveness in human tissues. The in vitro study of human lung tissues has been hampered by difficulties in growing and maintaining 3-Dimensional tissue in culture. The current technologies to achieve this, namely lung-on-a-chip, lung organoids, and precision-cut lung slices, have provided invaluable insights to our understanding of the human lung. While each of these technologies has its strengths and limitations, all are limited by the need for fresh tissues. Our study demonstrates that polyampholyte-based cryopreservation media can be used to preserve normal and diseased lung tissues in large batches. After cryopreservation, thawed microtissues displayed excellent viability, were metabolically active, and contained the major cell populations of the human lung. Our data is in agreement with previous studies demonstrating the advantages of using polyampholyte-based media as a cryopreservative (8, 9) . A notable finding in our study was that the human tissues tested displayed similar Another important component of our work was the demonstration of antiviral drug testing using primary human lung tissues, which represents an advance over the study of drugs in the context of non-physiologic cell lines. In this context, we confirmed the in vivo efficacy of dexamethasone and the ineffectiveness of chloroquine in suppressing viral growth in human tissues. An unexpected finding in our work was the lack of effect of remdesivir in both VeroE6 cells and human tissues, in contrast to prior studies in several cell lines (38) (39) (40) . One potential explanation for this discrepancy is that these studies used a much lower MOI (of 0.05 to 0.2), whereas we used an MOI of one in Vero cell cultures in order to inoculate with a virus titer equal to that used in our lung culture system. In this context, one study demonstrated that remdesivir exhibited potent antiviral activity in primary airway epithelial cells cultured using an air-liquid interface but was not effective in reducing viral titer in Vero cells, similar to our findings (38) . (25) (26) (27) , dexamethasone is thought only to inhibit the host response. Our data indicate that early viral replication in lung tissue may be linked to a corticosteroid-sensitive mechanism that involves the host response to infection. In summary, we provide evidence that human lung tissue can be utilized in vitro for the short-term study of SARS-CoV-2 infection. A lung tissue bank may also serve as a tool for the study of lung biology and drug screening beyond COVID-19, and facilitates the screening of multiple donors in parallel for purposes of toxicity and efficacy in primary human tissues. We envision that screening therapeutic agents in primary human tissue will take place after screening in cell lines, and in parallel with testing in animal models. Progenitor identification and SARS-CoV-2 infection in long-term human distal lung organoid cultures Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics Biochemistry of fish antifreeze proteins Toward a Molecular Understanding of the Mechanism of Cryopreservation by Polyampholytes: Cell Membrane Interactions and Hydrophobicity Cryopreservation of a Two-Dimensional Monolayer Using a Slow Vitrification Method with Polyampholyte to Inhibit Ice Crystal Formation Antifreeze Effect of Carboxylated ε-Poly-l-lysine on the Growth Kinetics of Ice Crystals Polyampholytes as Emerging Macromolecular Cryoprotectants Molecular Design of Polyampholytes for Vitrification-Induced Preservation of Three-Dimensional Cell Constructs without Using Liquid Nitrogen Improved protocol for simultaneous analysis of leukocyte subsets and epithelial cells from murine and human lung Morphometric characteristics of cells in the alveolar region of mammalian lungs Cell number and cell characteristics of the normal human lung Flow-cytometric method for simultaneous analysis of mouse lung epithelial, endothelial, and hematopoietic lineage cells Ruffles and spikes: Control of tight junction morphology and permeability by claudins Human Coronavirus-Associated Influenza-Like Illness in the Community Setting in Peru Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A Structural basis for human coronavirus attachment to sialic acid receptors Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Remdesivir for the Treatment of Covid-19 -Final Report Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19 Metformin and COVID-19: From cellular mechanisms to reduced mortality Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury Metformin and COVID-19: A novel deal of an old drug An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome Effect of obesity and body mass index on coronavirus disease 2019 severity: A systematic review and meta-analysis Predictive Factors for Severe Disease in Patients Hospitalised with COVID-19 in London, England: A Retrospective Cohort Study. ID 3638298. SSRN Scholarly Paper Characteristics, interventions, and longer term outcomes of COVID-19 ICU patients in Denmark-A nationwide, observational study Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses COPD, chronic obstructive pulmonary disease; IQR, interquartile range.